Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study

Support from human genetics increases the probability of success in drug development. However, few examples exist of successful genomically-driven drug repositioning. Given that a Mendelian form of severe enterocolitis is due to up-regulation of the interleukin-18 (IL18) signaling pathway, and pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Mokry, Lauren E., Zhou, Sirui, Guo, Cong, Scott, Robert A., Devey, Luke, Langenberg, Claudia, Wareham, Nick, Waterworth, Dawn, Cardon, Lon, Sanseau, Philippe, Davey Smith, George, Richards, J. Brent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599045/
https://www.ncbi.nlm.nih.gov/pubmed/31253830
http://dx.doi.org/10.1038/s41598-019-45747-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599045/
https://www.ncbi.nlm.nih.gov/pubmed/31253830
http://dx.doi.org/10.1038/s41598-019-45747-2

Ejemplares similares